Table of Contents Table of Contents
Previous Page  82 / 84 Next Page
Information
Show Menu
Previous Page 82 / 84 Next Page
Page Background

80

NCCN Guidelines for Patients

®

:

Colon Cancer, Version 1.2017

Index

Index

2

nd

opinion

68

ablation

34–35, 48, 52–53

biologic therapy

see targeted therapy

BRAF mutation

20–21

cancer staging

13

carcinoembryonic antigen (CEA)

18, 44, 51

carcinoma in situ

13

chemotherapy

26–31, 34–35, 38, 40–41, 43, 45,

48–50, 52–55, 57–61

clinical trial

32, 34–35, 43, 58–60, 65

colectomy

24–25, 35, 37–40, 45, 48–49

colonoscopy

16–17, 39, 44–45, 51–52

complete blood count (CBC)

18

computed tomography (CT)

16, 18–19, 44, 49, 51,

53–54

digestive tract

8–9

familial adenomatous polyposis (FAP)

15, 22

hereditary non-polyposis colon cancer (HNPCC)

15

lymphadenectomy

25, 35, 37–40, 43, 45

Lynch syndrome

15, 20–22

medical history

15–16, 44, 51

metastasectomy

25, 35, 48–49, 52–53

microsatellite instability (MSI)

42–43, 54–55, 57–61

mismatch repair

20–22, 42, 54, 58–61

NCCN Member Institutions

79

NCCN Panel Members

78

polypectomy

12–13, 37, 45

polyp

12–13, 24, 37–39, 45, 52

radiation therapy

32–34, 38, 41

RAS

16, 20, 57, 61

shared decision–making

63

supportive care

57–61

survivorship

44, 51

targeted therapy

28–31, 35, 50, 53–55, 58, 60